Skip to main content
Clinical Trials/ACTRN12618001430224
ACTRN12618001430224
Completed
Phase 2

Efficacy of Botulinum Toxin Type A in the Targeted Treatment of Nocturnal Bruxism: A Double-Blind, Randomised, Placebo-Controlled Cross-over Study

Melbourne Health0 sites41 target enrollmentAugust 27, 2018

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Melbourne Health
Enrollment
41
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 27, 2018
End Date
October 5, 2020
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Symptoms of nocturnal bruxism of adequate severity as measured by overnight monitoring.

Exclusion Criteria

  • Contraindication to botulinum toxin administration, concurrent use of medications affecting muscle relaxation, prior history of severe jaw trauma, orofacial pain of an alternate aetiology, neuromuscular disease, major respiratory disease(s) that may preclude overnight EMG recordings, administration of botulinum toxin for other indication (including cosmetic) within 16weeks of study commencement.

Outcomes

Primary Outcomes

Not specified

Similar Trials